In last trading session, Marinus Pharmaceuticals Inc (NASDAQ:MRNS) saw 0.31 million shares changing hands with its beta currently measuring 1.04. Company’s recent per share price level of $6.17 trading at $0.07 or 1.15% at ring of the bell on the day assigns it a market valuation of $336.70M. That closing price of MRNS’s stock is at a discount of -80.71% from its 52-week high price of $11.15 and is indicating a premium of 43.92% from its 52-week low price of $3.46. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.48 million shares which gives us an average trading volume of 594.17K if we extend that period to 3-months.
For Marinus Pharmaceuticals Inc (MRNS), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.27. Splitting up the data highlights that, out of 11 analysts covering the stock, 0 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 9 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.63 in the current quarter.
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) trade information
Upright in the green during last session for gaining 1.15%, in the last five days MRNS remained trading in the green while hitting it’s week-highest on Wednesday, 11/15/23 when the stock touched $6.17 price level, adding 8.59% to its value on the day. Marinus Pharmaceuticals Inc’s shares saw a change of 55.03% in year-to-date performance and have moved 3.52% in past 5-day. Marinus Pharmaceuticals Inc (NASDAQ:MRNS) showed a performance of -8.73% in past 30-days. Number of shares sold short was 4.43 million shares which calculate 11.51 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $20.00 to the stock, which implies a rise of 69.15% to its current value. Analysts have been projecting $9.00 as a low price target for the stock while placing it at a high target of $28.00. It follows that stock’s current price would drop -353.81% in reaching the projected high whereas dropping to the targeted low would mean a loss of -45.87% for stock’s current value.
Marinus Pharmaceuticals Inc (MRNS) estimates and forecasts
Statistics highlight that Marinus Pharmaceuticals Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -24.01% of value to its shares in past 6 months, showing an annual growth rate of -390.20% while that of industry is 10.50. Apart from that, the company came lowering its revenue forecast for fiscal year 2023. The company is estimating its revenue growth to increase by 17.10% in the current quarter and calculating 11.90% increase in the next quarter. This year revenue growth is estimated to rise 23.80% from the last financial year’s standing.
11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $7.75 million for the same. And 8 analysts are in estimates of company making revenue of $8.53 million in the next quarter that will end on Mar 2024. Company posted $7.16 million and $10.38 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 8.20% while estimating it to be -17.80% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 30.82% during past 5 years. In 2023, company’s earnings growth rate is likely to be around -395.54% while estimates for its earnings growth in next 5 years are of 20.00%.
Marinus Pharmaceuticals Inc is more likely to be releasing its next quarterly report on November 07 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Marinus Pharmaceuticals Inc (NASDAQ:MRNS)’s Major holders
Insiders are in possession of 0.78% of company’s total shares while institution are holding 86.41 percent of that, with stock having share float percentage of 87.09%. Investors also watch the number of corporate investors in a company very closely, which is 86.41% institutions for Marinus Pharmaceuticals Inc that are currently holding shares of the company. Suvretta Capital Management, LLC is the top institutional holder at MRNS for having 4.06 million shares of worth $44.07 million. And as of Jun 29, 2023, it was holding 8.02% of the company’s outstanding shares.
The second largest institutional holder is Blackrock Inc., which was holding about 3.9 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 7.70% of outstanding shares, having a total worth of $42.33 million.
On the other hand, Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 3.17 million shares of worth $34.46 million or 6.27% of the total outstanding shares. The later fund manager was in possession of 1.46 million shares on Jun 29, 2023, making its stake of worth around $15.8 million in the company or a holder of 2.88% of company’s stock.